Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution... see more

TSXV:WAVE - Post Discussion

Waverley Pharma Inc > Great 👍, , Waves cancer drug approved in Europe
View:
Post by moneywinner1 on Sep 14, 2020 9:03am

Great 👍, , Waves cancer drug approved in Europe

Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries

Comment by moneywinner1 on Sep 14, 2020 9:49am
With SARS whining slowly , the next huge snd long story will be cancer drugs again , I'm loading Wave , approved USA sales and Approved Europe sales  makes this new company  Wave a huge target 
Comment by bigkagan on Sep 14, 2020 3:22pm
they say that the US market for these drugs is $3 bil. - even if they capture only 10% it's gonna  be huge
Comment by moneywinner1 on Sep 15, 2020 8:43am
This is just a start of a company 
Comment by MirrorWorldMan on Sep 15, 2020 10:09am
I agree and like the news out of Europe and the US.  The cash bleed is an issue though, as it is with most promising companies of this size and I am interested to see what they do with Pemetrexed to bring in some revenue.   The ANDA submission for the six generics in the US should not be that expensive to do, (even with consultants).  The time to approval should be short as per ...more  
Comment by bigkagan on Sep 15, 2020 2:40pm
they also need sales people to sell these drugs, they don't sell themselves
Comment by bigkagan on Sep 15, 2020 2:43pm
there is also a website which keeps track of how many drugs are being sold by a company, I forgot its name but I used to check it in the past when I had a junior pharma company similar to this
Comment by moneywinner1 on Sep 17, 2020 11:34am
CEO and management must learn that without public knowledge of Wave there is no value . Get some news CEO and change Market makers to professionals with knowledge 
Comment by MirrorWorldMan on Sep 18, 2020 9:10am
No doubt about it,these guys need cash soon.  Likely within the next quarter.  Even with potential help from any comercial partners their cash burn is at least .5 MM a quarter.  As low and respected as that is, their cash and receiveables are not enough to get them to the new year by my calculations and its a miracle they got through this far. I have seen this before in a high ...more  
Comment by Abito on Oct 02, 2020 11:43pm
i agree... and the way its trading in such a tight reange thier might be a financing in the works.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities